Mike Seganish

Michael has worked at MSD for 18 years in the discovery chemistry group. Over the past 6 years he has focused on building capabilities in ADCs and targeted delivery at the South San Francisco, California site. These efforts have focused on novel ADC targets, novel payloads as well as novel formats including peptide drug conjugates, the results of which have been a rapidly growing preclinical as well as late-stage clinical pipeline of novel ADCs.